Valvular & structural heart disease
Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: 3-Year Outcomes From the TRILUMINATE Study
Authors' conclusion
In the longest follow-up to date of any T-TEER therapy, the TRILUMINATE study demonstrated that the TriClip procedure is both safe and effective, with sustained benefits at 3 years in subjects with symptomatic moderate or greater TR.
Study context
- Population
- Patients with symptomatic moderate or greater tricuspid regurgitation (TR)
- Participants
- 98 patients
Methodological detailsinternational, multicenter, core laboratory echocardiography
- International
- Multicenter
- Core laboratory echocardiography
Main finding
As reported in the abstract
TR severity · 3 years
TR reduced to moderate or less
79%
TR reduction of at least 1 grade
92%
Observational data: associations, not effects.
Further findings
Durability of TR reduction, NYHA class and KCCQ quality of life · 3 years
- TR reduction achieved at 1 year sustained through 3 years
- Improvement in NYHA class and KCCQ vs baseline
Site-reported HF hospitalisation rate · 1 year before vs 3 years after implantation
- HF hospitalisation rate 1 year before implantation
- 0.56 events/patient-year
- HF hospitalisation rate 3 years after implantation
- 0.14 events/patient-year
- Reduction
- 75% (P < 0.0001)
Original publication
Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: 3-Year Outcomes From the TRILUMINATE Study. JACC Cardiovasc Interv. Published 4 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it